Skip to main content
. 2019 May 29;8:212581. doi: 10.7573/dic.212581

Figure 8.

Figure 8

Proportion of subjects with complete resolution of ≥1 target tophus in CRYSTAL extension study. Patients continued core lesinurad 200 mg plus febuxostat treatment (200 CONT) or crossed over from core febuxostat alone to lesinurad 200 mg plus febuxostat (200 CROSS).27